Cited by 762Systemic Lupus Erythematosus ResearchSystemic Sclerosis and Related DiseasesClinical practice guidelines implementation

The DOI matches its Crossref record; 159 of the 164 references it cites were found in a registry or an index.

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

Open access

Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T·2008·Annals of the Rheumatic Diseases

DOI 10.1136/ard.2007.070367

Open this paper in CoChat — free account

Abstract

Objective Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE. Methods The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Key questions for the management of SLE were compiled using the Delphi technique. A systematic search of PubMed and Cochrane Library Reports was performed using McMaster/Hedges clinical queries' strategies for questions related to the diagnosis, prognosis, monitoring and treatment of SLE. For neuropsychiatric, pregnancy and antiphospholipid syndrome questions, the search was conducted using an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence, and agreement on the statements was measured across the 19 specialists. Results Twelve questions were generated regarding the prognosis, diagnosis, monitoring and treatment of SLE, including neuropsychiatric SLE, pregnancy, the antiphospholipid syndrome and lupus nephritis. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements. The average agreement among experts was 8.8 out of 10. Conclusion Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.

Integrity signals

Registry

Crossref · 10.1136/ard.2007.070367

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citation
Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric Transplant
Wolfe, R. A., Ashby, V. B., Milford, E. L., OJO, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,370
Systemic Lupus Erythematosus
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Competing interests: none declared.
Hirsch, L. (2006) · Cited by 1,396
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Therapy of Lupus Nephritis
Austin, H. A., Klippel, J. H., Balow, J. E., LeRICHE, N. G. H., Steinberg, A. D., Plötz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,189
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M., KALUNIAN, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M. D., Merrill, J. T., Belmont, M. H., Askanase, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C. B., Kim, M., Buyon, J. P., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,122
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F., Tang, C. S.-O., Wong, R. W. S., Fang, G. X., Ji, Y., Lau, C. S., Wong, A. K., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 949

Flagged first, then by citations

Show all 164 references

5 of the 164 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

2001, AGREE Instrument., The AGREE collaboration

Sorted by citations

Items 301–400 of 760

Autoimmunity in visual loss
Petzold, A., Wong, S. H., & Plant, G. T. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63432-0.00020-7 · Cited by 22
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients
Chavatza, K., Kostopoulou, M., Nikolopoulos, D., Gioti, O., Togia, K., Andréoli, L., Aringer, M., Boletis, J., Doria, A., Houssiau, F., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220438 · Cited by 21
Systemic lupus erythematosus: modern strategies for management – a moving target
King, J. K., & Hahn, B. H. (2007) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2007.09.002 · Cited by 18
Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus
Miyagawa, I., Nakano, K., Nakayamada, S., Iwata, S., Hanami, K., Fukuyo, S., Kubo, S., Inoue, Y., Ueno, M., & Tanaka, Y. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13387 · Cited by 20
Progression of atherosclerosis versus arterial stiffness with age within and between arteries in systemic lupus erythematosus
Roldan, P. C., Greene, E. R., Qualls, C., Sibbitt, W. L., & Roldan, C. A. (2019) · Rheumatology International · doi:10.1007/s00296-019-04267-y · Cited by 20
Classification of Lupus Nephritis; Time for a Change?
Stokes, M. B., & D’Agati, V. D. (2019) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2019.06.002 · Cited by 20
Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients
Harris, J. G., Maletta, K. I., Kuhn, E. M., & Olson, J. C. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3518-0 · Cited by 20
Treatment Update in Systemic Lupus Erythematous
Hoi, A. Y.-B., & Morand, E. F. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.012 · Cited by 19
Primary prevention in antiphospholipid antibody carriers
Bertero, M. (2012) · Lupus · doi:10.1177/0961203312445229 · Cited by 19
Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids
Nawata, K., Nakamura, J., Ikeda, K., Furuta, S., Nakajima, H., Ohtori, S., Hagiwara, S., Wako, Y., Miura, M., Kawarai, Y., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key009 · Cited by 19
Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus
Hernández‐Breijo, B., Gómez, A., Soukka, S., Johansson, P., & Parodis, I. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102372 · Cited by 19
Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators
Gillis, J. Z., Panopalis, P., Schmajuk, G., Ramsey‐Goldman, R., & Yazdany, J. (2010) · Arthritis Care & Research · doi:10.1002/acr.20327 · Cited by 19
Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology
Berntsson, S. G., Katsarogiannis, E., Lourenço, F., & Moraes‐Fontes, M. F. (2016) · Case Reports in Neurology · doi:10.1159/000444874 · Cited by 19
Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series
Chessa, E., Piga, M., Floris, A., Mathieu, A., & Cauli, A. (2017) · Reumatismo · doi:10.4081/reumatismo.2017.1007 · Cited by 19
Measuring educational needs among patients with systemic lupus erythematosus (SLE) using the Dutch version of the Educational Needs Assessment Tool (D-ENAT)
Zirkzee, E. J. M., Ndosi, M. E., Vlieland, T. P. M. V., & Meesters, J. J. L. (2014) · Lupus · doi:10.1177/0961203314544188 · Cited by 18
Sharp decline in hydroxychloroquine dosing—analysis of 17,797 initiators from 2007 to 2016
Melles, R. B., Jorge, A. M., Marmor, M. F., Zhang, Y., & Choi, H. K. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4116-0 · Cited by 18
Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus
Hrušková, Z., & Tesař, V. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1504918 · Cited by 18
High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus
Chen, M., Wu, C., Chen, M., Tsai, C., Lee, F., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179116 · Cited by 18
Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
Gordon, C., Bassi, R., Chang, P., Kao, A. H., Jayne, D. R. W., Wofsy, D., & Fleuranceau-Morel, P. (2019) · Rheumatology Advances in Practice · doi:10.1093/rap/rkz021 · Cited by 18
Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis
Klumb, E. M., Silva, C. A., Lanna, C. C. D., Sato, E. I., Borba, E. F., Brenol, J. C. T., de Albuquerque, E. M. D. N., Monticielo, O. A., Costallat, L. T. L., Latorre, L. C., et al. (2015) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2014.09.010 · Cited by 18
Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000–2017
Kariniemi, S., Rantalaiho, V. M., Virta, L. J., Puolakka, K., Sokka‐Isler, T., & Elfving, P. (2020) · Lupus · doi:10.1177/0961203320967102 · Cited by 17
Increased Proportion of CD226+ B Cells Is Associated With the Disease Activity and Prognosis of Systemic Lupus Erythematosus
Nakano, M., Ayano, M., Kushimoto, K., Kawano, S., Higashioka, K., Inokuchi, S., Mitoma, H., Kimoto, Y., Akahoshi, M., Ono, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713225 · Cited by 16
Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: The LUCIE Study
Cervera, R., Rúa‐Figueroa, Í., Gil‐Aguado, A., Sabio, J. M., Pallarés, L., Hernández-Pastor, L. J., & Iglesias, M. (2013) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2013.03.001 · Cited by 17
Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser
Scheinberg, M. A., Hislop, C., & Martin, R. S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1169270 · Cited by 17
Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus by the Mexican College of Rheumatology
Xibille-Friedmann, D. X., Pérez‐Rodríguez, M., Carrillo-Vázquez, S. M., Hernández, E. A., Aceves, F. J., Ocampo-Torres, M. C., García-García, C., García‐Figueroa, J. L., Merayo‐Chalico, J., Barrera‐Vargas, A., et al. (2018) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2018.03.003 · Cited by 17
Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy
Chen, M.-H., Chen, M.-H., Tsai, C.-Y., Chou, C.-T., Lin, H.-Y., Huang, D.-F., & Huang, Y.-H. (2015) · Lupus · doi:10.1177/0961203315571465 · Cited by 17
Accumulation of Fat Not Responsible for Femoral Head Necrosis, Revealed by Single-Cell RNA Sequencing: A Preliminary Study
Wang, Y., Li, D., Chen, H., Li, Z., Feng, B., & Weng, X. (2023) · Biomolecules · doi:10.3390/biom13010171 · Cited by 17
Juvenile systemic lupus erythematosus in Portugal: clinical and immunological patterns of disease expression in a cohort of 56 patients.
Cabral, M., Escobar, C., Conde, M., Ramos, M., & Gomes, J. A. M. (2013) · PubMed · Cited by 16
Characteristics of azathioprine use and cessation in a longitudinal lupus cohort
Croyle, L., Hoi, A. Y.-B., & Morand, E. F. (2015) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000105 · Cited by 16
Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre
Bortoluzzi, A., J, M. P. J., Farina, I., Galuppi, E., Leonardis, F. D., & Govoni, M. (2012) · Reumatismo · doi:10.4081/reumatismo.2012.350 · Cited by 16
Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results
Takeuchi, T., Okada, K., Yoshida, H., & Yagi, N. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1349573 · Cited by 16
Dry eye disease flares: A rapid evidence assessment
Starr, C. E., Dana, R., Pflugfelder, S. C., Holland, E. J., Zhang, S., Owen, D. V., & Brazzell, K. (2021) · The Ocular Surface · doi:10.1016/j.jtos.2021.07.001 · Cited by 16
Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study
Manger, B., Hiepe, F., Wimmer, P., Paulus, E., Schneider, M., Worm, M., & Schwarting, A. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s81922 · Cited by 16
Lupus nephritis—winning a few battles but not the war
Bertsias, G. K., & Boumpas, D. T. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.88 · Cited by 16
Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations
Orsolini, G., Bultink, I. E. M., Adami, G., Fassio, A., Viapiana, O., Giollo, A., Gatti, D., & Rossini, M. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215896 · Cited by 15
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses
Flórez, H., Hernández‐Rodríguez, J., Carrasco, J. L., Prieto‐González, S., Muxí, Á., Filella, X., Ruiz-Gaspà, S., Gómez-Puerta, J. A., Cid, M. C., Espinosa, G., et al. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001355 · Cited by 14
ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status?
Klonizakis, P., Tselios, K., Sarantopoulos, A., Gougourellas, I., Rouka, E. C., Onufriadou, Z., Kapali, P., Kyriakou, D. S., & Boura, P. (2013) · Lupus · doi:10.1177/0961203313477898 · Cited by 15
Broad Concepts in Management of Systemic Lupus Erythematosus
CHOWDHARY, V. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.007 · Cited by 15
Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study
Furie, R. A., Mitrane, M., Zhao, E., & Becker, P. M. (2017) · Lupus Science & Medicine · doi:10.1136/lupus-2017-000240 · Cited by 15
The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients
Mousa, T. G., Omar, H. H., Emad, R., Salama, M. I., Omar, W., Fawzy, M., & Hassoba, H. M. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4349-y · Cited by 15
Postpartum care of women with renal disease
Pillay, C., & Clark, K. (2019) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2019.03.008 · Cited by 15
Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial
Zanetti, C. B., Pedrosa, T. D. N., Kupa, L. D. V. K., Aikawa, N. E., Borba, E. F., Vendramini, M. B. G., Silva, C. A., Pasoto, S. G., & Bonfá, E. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05600-2 · Cited by 15
Cardiac tamponade as the first manifestation of systemic lupus erythematosus in children: Table 1
Arabi, M. T., Malek, E. M., Fares, M., & Itani, M. H. (2012) · BMJ Case Reports · doi:10.1136/bcr-2012-006927 · Cited by 15
A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?
Boumpas, D. T., Bertsias, G. K., & Balow, J. E. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.139683 · Cited by 15
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study
Miettunen, P., Pistorio, A., Palmisani, E., Ravelli, A., Silverman, E. D., de Oliveira, S. K. F., Alessio, M., Cuttica, R. J., Mihaylova, D., Espada, G., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201937 · Cited by 15
Attenuation of nephritis in lupus-prone mice by thalidomide
Lee, S., Park, Y.-B., Yang, J., Park, K.-H., Lee, S., Choi, K. H., & Kim, B. S. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes227 · Cited by 15
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study
Monahan, R. C., de Voorde, L. J. J. B.-V., Fronczek, R., de Bresser, J., Eikenboom, J. C. J., Kloppenburg, M., Middelkoop, H. A. M., Terwindt, G. M., van der Wee, N. J. A., Huizinga, T. W. J., et al. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000850 · Cited by 14
Antiphospholipid Syndrome: State of the Art of Clinical Management
Depietri, L., Veropalumbo, M. R., Leone, M. C., & Ghirarduzzi, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07496-3 · Cited by 16
Toward electronic health recording: evaluation of electronic patient reported outcome measures (e-PROMs) system for remote monitoring of early systemic lupus patients
Miedany, Y. M. E., Gaafary, M. M. E., Aroussy, N. E., Bahlas, S. M., Hegazi, M. O., Palmer, D., & Youssef, S. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3675-9 · Cited by 14
Treat to Target in Systemic Lupus Erythematosus
Aringer, M., Leuchten, N., & Schneider, M. (2019) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2019.07.004 · Cited by 14
The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus
Miyagawa, I., Nakano, K., Nakayamada, S., Iwata, S., Hanami, K., Fukuyo, S., Kubo, S., Kawabe, A., Miyazaki, Y., Inoue, Y., et al. (2020) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13792 · Cited by 14
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence
Osmani, Z., Schrama, T. J., Zacouris-Verweij, W., Andersen, J., Frankel, S., Bultink, I. E. M., Cornet, A., & van Vollenhoven, R. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000478 · Cited by 16
Diagnostic accuracy of the European League against rheumatism/American College of Rheumatology-2019 versus the Systemic Lupus International Collaborating Clinics-2012 versus the ACR-1997 classification criteria in adult systemic lupus erythematosus: A systematic review and meta-analysis
Lu, W., Tian, F., Ma, J., Zhong, Y., Liu, Z., & Xue, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023451 · Cited by 16
Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus
Tselios, K., Sarantopoulos, A., Gkougkourelas, I., Papagianni, A. A., & Boura, P. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12500 · Cited by 14
Systemic lupus erythematosus and pregnancy
Gáti, T., Pajor, A., Géher, P., & Nagy, G. (2008) · Orvosi Hetilap · doi:10.1556/oh.2008.28295 · Cited by 14
Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis?
Marques, M. G., Cotovio, P., Ferrer, F. A. D., Silva, C., Botelho, C., Lopes, K., Maia, P., Carreira, A., & Campos, M. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sft118 · Cited by 14
Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management
Trujillo‐Martín, M. M., de Larrinoa, Í. R.-F. F., Ruiz‐Irastorza, G., Pego‐Reigosa, J. M., Sabio, J. M., & Serrano-Aguilar, P. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.06.033 · Cited by 14
Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration
Poh, Y. J., Baptista, B. J. A., & D’Cruz, D. P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1371592 · Cited by 14
Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey
Birt, J. A., Hadi, M. A., Sargalo, N., Brookes, E., Swinburn, P., Hanrahan, L. M., Tse, K., Bello, N., Griffing, K., Silk, M. E., et al. (2021) · Rheumatology and Therapy · doi:10.1007/s40744-021-00328-6 · Cited by 14
The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: A systematic review and meta-analysis
Tian, Y., Xu, J., Chen, D., Yang, C., & Peng, B. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102121 · Cited by 13
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2
Wahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41772 · Cited by 17
Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases
Sheu, H.-S., Chen, Y., Liao, Y., Wei, C., Chen, J., Lin, H., Hung, W., Huang, W., & Chen, Y. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091399 · Cited by 13
Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort
Ding, Y., Zhou, Y., Zhan, F., Xu, J., Duan, X., Luo, H., Zhao, C., Yang, M., Wu, R., Wu, L., et al. (2024) · Med · doi:10.1016/j.medj.2024.06.005 · Cited by 13
Belimumab in the management of systemic lupus erythematosus – an update
Tesař, V., & Hrušková, Z. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1324846 · Cited by 13
Bulgarian rheumatology: science and practice in a cost-constrained environment
Georgiev, T., & Stoilov, R. M. (2018) · Rheumatology International · doi:10.1007/s00296-018-4202-2 · Cited by 14
Target Therapy in SLE
Schneider, M. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.07.007 · Cited by 13
Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice
Anandi, P., Dickson, A. L., Feng, Q., Wei, W., Dupont, W. D., Plummer, D., Liu, G., Octaria, R., Barker, K. A., Kawai, V. K., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0163-4 · Cited by 13
Deep Breathing Increases Heart Rate Variability in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rovsing, C., Rovsing, H., Liboriussen, C. H., Jensen, M. K., Andersen, S. S., Andersen, S. S., Kristensen, S., & Jochumsen, M. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001300 · Cited by 15
Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes
der DGRh, K. P., Aringer, M., Fischer‐Betz, R., & Hiepe, F. (2013) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-013-1213-y · Cited by 13
Aortic Atherosclerosis in Systemic Lupus Erythematosus
Roldan, P. C. (2013) · Rheumatology Current Research · doi:10.4172/2161-1149.s5-006 · Cited by 13
Chloroquine‐induced subacute paranoid‐like disorder as a complication of dermatological treatment
Bogaczewicz, A., Sobów, T., Bogaczewicz, J., Bieńkowski, P., Kowalski, J., & Woźniacka, A. J. (2016) · International Journal of Dermatology · doi:10.1111/ijd.13266 · Cited by 13
Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis
Garnier, C., Ribes, D., Chauveau, D., Huart, A., Pugnet, G., Adoué, D., Prévôt, G., Alric, L., Delobel, P., Derumeaux, H., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.180310 · Cited by 13
Sample stability and variability of B‐cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus
Belouski, S. S., Wallace, D. J., Weisman, M. H., ISHIMORI, M. L., Hendricks, L., Zack, D. J., Vincent, M., Rasmussen, E., Ferbas, J., & Chung, J. B. (2009) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20482 · Cited by 13
The outcome of patients with lupus nephritis and the impact of cardiovascular risk factors.
Drakoulogkona, O., Bărbulescu, A. L., Rica, I., Mușetescu, A. E., & Ciurea, P. L. (2011) · Europe PMC (PubMed Central) · Cited by 13
Pitfalls in lupus
Schneider, M. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.033 · Cited by 12
Cardiac Magnetic Resonance Imaging T1 and T2 Mapping in Systemic Lupus Erythematosus in Relation to Antimalarial Treatment
Shalmon, T., Thavendiranathan, P., Seidman, M. A., Wald, R. M., Karur, G. R., Harvey, P., Akhtari, S., Osuntokun, T., Tselios, K., Gladman, D. D., et al. (2023) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000703 · Cited by 12
Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic
Seo, M. R., Kim, J., Park, E.-J., Jung, S. M., Sung, Y., Kim, H., Kim, G., Kim, H., Lee, M. S., Lee, J., et al. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.417 · Cited by 12
The association between active proliferative lupus nephritis during pregnancy and small for gestational age newborns
Lacerda, M. I., Rodrigues, B. C., de Jesús, G. R., dos Santos, F. C., de Jesús, N. R., Levy, R. A., & Klumb, E. M. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/xspect · Cited by 12
Drugs used in incident systemic lupus erythematosus – results from the Finnish nationwide register 2000–2007
Elfving, P., Puolakka, K., Kautiainen, H., Virta, L. J., Pohjolainen, T., & Kaipiainen‐Seppänen, O. (2016) · Lupus · doi:10.1177/0961203316628998 · Cited by 12
Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus
Sabato, L. A., Mendes, L. A., & Cox, Z. L. (2016) · Journal of Pharmacy Practice · doi:10.1177/0897190016655726 · Cited by 12
Comparison of Plasma Cytokine Levels before and after Treatment with Rituximab in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus-Associated Polyautoimmunity
Correa, J. E. B., Franco, M. A., Ángel, J., & Rodríguez, L. (2018) · Universitas Médica · doi:10.11144/javeriana.umed59-3.cyto · Cited by 13
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome
Wind, M., Hendriks, M., van Brussel, B. T. J., Eikenboom, J. C. J., Allaart, C. F., Lamb, H. J., Siebelink, H. J., Ninaber, M. K., van Geloven, N., Lith, J. M. M. V., et al. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000472 · Cited by 12
Comparison of the sensitivity of the EULAR / ACR 2019 and SLICC 2012 classification criteria in a Colombian population with systemic lupus erythematosus
Guavita-Navarro, D., Gallego-Cardona, L., Arredondo, A. M., Cubides, H. H., Cajamarca-Barón, J., Ibáñez, C., Escobar, A., & Rojas‐Villarraga, A. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100133 · Cited by 11
Exploring new territory: considering the future
Schneider, M. (2007) · Lupus · doi:10.1177/0961203306075615 · Cited by 12
Update on Biologic Therapies for Systemic Lupus Erythematosus
Borba, H. H. L., Funke, A., Wiens, A., Utiyama, S. R. R., Perlin, C. M., & Pontarolo, R. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0589-5 · Cited by 11
The management of systemic lupus erythematosus: Facts and controversies
Elbirt, D., Sthoeger, D., Asher, I., & Sthoeger, Z. M. (2010) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2009.06.017 · Cited by 11
Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Pinto, R. D., Pietropaoli, D., Monaco, A., Desideri, G., Ferri, C., & Grassi, D. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200403122600 · Cited by 11
How to treat refractory arthritis in lupus?
Artifoni, M., & Puéchal, X. (2012) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.12.010 · Cited by 11
Systemischer Lupus erythematodes
Aringer, M., & Hiepe, F. (2011) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-011-0794-6 · Cited by 11
Schwangerschaft bei entzündlich-rheumatischen Erkrankungen
Fischer‐Betz, R., & Gromnica‐Ihle, E. (2010) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-010-0661-x · Cited by 11
Predisposing factors to nonfatal cardiovascular events in women with systemic lupus erythematosus. An observational, cross-sectional, multicenter study in Spain from the risk/systemic lupus erythematosus thematic network
Fernández‐Garcés, M., Haro, G., & Micó, M. L. (2019) · Medicine · doi:10.1097/md.0000000000017489 · Cited by 11
Treatment of thrombotic antiphospholipid syndrome in adults and children
Madison, J. A., Duarte‐García, A., Zuo, Y., & Knight, J. S. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000702 · Cited by 12
Epidemiology and risk factors for chronic kidney disease in C hinese patients with biopsy‐proven lupus nephritis
Sui, M., Ye, X., Ma, J., Yu, C., Zhao, S., Liu, X., Li, L., Cao, J., Jia, X., & Xie, R. (2015) · Internal Medicine Journal · doi:10.1111/imj.12840 · Cited by 11
Automatic Segmentation of the Corpus Callosum Using a Cell-Competition Algorithm
Lee, S.-P., Wu, C., Cheng, J., Chen, C., Chen, Y.-C., & Chou, M. (2015) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000282 · Cited by 11
Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey
Plüß, M., Chehab, G., & Korsten, P. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217967 · Cited by 11
Autoantibodies against dsDNA measured with nonradioactive Farr assay-an alternative for routine laboratories
Lakota, K., Švec, T., Kveder, T., Sodin-Šemrl, S., Žigon, P., Ambrožič, A., Ogrič, M., Markez, S., Božič, B., Tomšič, M., et al. (2019) · Clinical Rheumatology · doi:10.1007/s10067-018-4271-3 · Cited by 10
Oxford Desk Reference: Rheumatology
Hall, F. C., & Marshall, T. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199229994.001.0001 · Cited by 10
Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
YAMADA, M., Akita, M., Nakagawa, T., Takahashi, N., Endo, A., & Yoshida, P. (2013) · Journal of Drug Assessment · doi:10.3109/21556660.2013.792823 · Cited by 10
Diagnosis and treatment of childhood-onset systemic lupus erythematosus (European evidence-based recommendations from the SHARE initiative)
Smith, E. M. D., Sen, E. S., & Pain, C. E. (2018) · Archives of Disease in Childhood Education & Practice · doi:10.1136/archdischild-2017-314049 · Cited by 10
2008–2018: a decade of recommendations for systemic lupus erythematosus
Boumpas, D. T., Bertsias, G. K., & Fanouriakis, A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214014 · Cited by 10

Authors: Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., Isenberg, D., Kallenberg, C. G. M., Khamashta, M., Piette, J. C., Schneider, M., Smolen, J., Sturfelt, G., Tincani, A., van Vollenhoven, R., Gordon, C., & Boumpas, D. T.
Affiliations: University of Crete (GR)
University of Ioannina (GR)
Laiko General Hospital of Athens (GR)
University of Pisa (IT)
Hospital Clínic de Barcelona (ES)
Oslo University Hospital (NO)
Cliniques Universitaires Saint-Luc (BE)
Leiden University Medical Center (NL)
University College Hospital (GB)
University Medical Center Groningen (NL)
St Thomas' Hospital (GB)
Heinrich Heine University Düsseldorf (DE)
Medical University of Vienna (AT)
Lund University (SE)
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
University of Birmingham (GB)
Corresponding author: Boumpas, D T
ORCID: Bertsias, G
Ioannidis, J P A
Bombardieri, S
Cervera, R
Huizinga, T
Isenberg, D
Khamashta, M
Schneider, M
Smolen, J
Tincani, A
Gordon, C
Boumpas, D T
Venue: Annals of the Rheumatic Diseases
Publisher: Elsevier BV
Published: 2008-02
Volume: 67
Issue: 2
Pages: 195-205
ISSN: 0003-4967 (ISSN-L)
DOI: 10.1136/ard.2007.070367
OpenAlex: W2157038471
Cited by: 762
References: 164
Citations by year: 2026: 14 · 2025: 17 · 2024: 19 · 2023: 26 · 2022: 19 · 2021: 58 · 2020: 56 · 2019: 53 · 2018: 70 · 2017: 62 · 2016: 47 · 2015: 53 · 2014: 43 · 2013: 53 · 2012: 46
FWCI: 18.49
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor)
Locations: Annals of the Rheumatic Diseases (publishedVersion)
PubMed (publishedVersion)
Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
Lund University Publications (Lund University) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders: University of Crete
Topics: Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords: systemic lupus erythematosus, clinical management, diagnosis, prognosis, disease surveillance, treatment, neuropsychiatric lupus, pregnancy, antiphospholipid syndrome, lupus nephritis, evidence-based recommendations, expert consensus
MeSH terms: Female, Humans, Lupus Erythematosus, Systemic, Lupus Nephritis, Male, Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks